Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection, concentrated - excipient ingredients: nitrogen; water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection, concentrated - excipient ingredients: water for injections; nitrogen - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - vinorelbine as tartrate - capsules - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - vinorelbine as tartrate - capsules - vinorelbine as tartrate 30 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

Canada - English - Health Canada

sandoz canada incorporated - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents

Canada - English - Health Canada

mylan pharmaceuticals ulc - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents

Canada - English - Health Canada

fresenius kabi canada ltd - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - vinorelbine (vinorelbine tartrate) - concentrate for solution for infusion - 10mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - vinorelbine (vinorelbine tartrate) - concentrate for solution for infusion - 10mg/ml

United States - English - NLM (National Library of Medicine)

hospira, inc. - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine 10 mg in 1 ml - vinorelbine injection, usp is indicated: none pregnancy category d risk summary vinorelbine can cause fetal harm when administered to a pregnant woman. in animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus. animal data in a mouse embryofetal development study, administration of a single dose of vinorelbine at a dose level of 9 mg/m2 or greater (approximately 0.33 times the recommended human dose based on body surface area) was embryotoxic and fetotoxic. vinorelbine was embryotoxic and fetotoxic to pregnant rabbits when administered every 6 days during the period of organogenesis at doses of 5.5 mg/m2 (approximately 0.18 times the recommended human dose based on body surface area) or greater. at doses t